Abstract
We hypothesized that the abundance of PD1 mRNA in tumor samples might explain the differences in overall response rates (ORR) observed following anti-PD1 monotherapy across cancer types. RNASeqv2 data from 10 078 tumor samples representing 34 different cancer types was analyzed from TCGA. Eighteen immune-related gene signatures and 547 immune-related genes, including PD1, were explored. Correlations between each gene/signature and ORRs reported in the literature following anti-PD1 monotherapy were calculated. To translate the in silico findings to the clinical setting, we analyzed the expression of PD1 mRNA using the nCounter platform in 773 formalin-fixed paraffin embedded (FFPE) tumor samples across 17 cancer types. To test the direct relationship between PD1 mRNA, PDL1 immunohistochemistry (IHC), stromal tumor-infiltrating lymphocytes (sTILs) and ORR, we evaluated an independent FFPE-based dataset of 117 patients with advanced disease treated with anti-PD1 monotherapy. In pan-cancer TCGA, PD1 mRNA expression was found strongly correlated (r > 0.80) with CD8 T-cell genes and signatures and the proportion of PD1 mRNA-high tumors (80th percentile) within a given cancer type was variable (0%-84%). Strikingly, the PD1-high propor...Continue Reading
References
Mar 16, 2012·Nature Reviews. Cancer·Wolf Herman FridmanJérôme Galon
Aug 16, 2013·Nature·Ludmil B AlexandrovMichael R Stratton
Mar 29, 2014·The Journal of Clinical Investigation·Alena GrosSteven A Rosenberg
Sep 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R SalgadoUNKNOWN International TILs Working Group 2014
Apr 4, 2015·Science·Padmanee Sharma, James P Allison
Nov 13, 2015·JAMA Oncology·Joseph McLaughlinDavid L Rimm
Dec 18, 2015·Journal for Immunotherapy of Cancer·Alessandra Cesano
Mar 14, 2016·Lancet·Louis FehrenbacherUNKNOWN POPLAR Study Group
Aug 16, 2016·The Journal of Clinical Investigation·Adil I DaudMichael D Rosenblum
May 11, 2017·Cancer Research·Aleix PratEnriqueta Felip
Jun 27, 2017·The Journal of Clinical Investigation·Mark AyersTerrill K McClanahan
Aug 25, 2017·Molecular Cancer Therapeutics·Aaron M GoodmanRazelle Kurzrock
Dec 21, 2017·The New England Journal of Medicine·Mark YarchoanElizabeth M Jaffee
Apr 7, 2018·Cell·Katherine A HoadleyPeter W Laird
Jun 13, 2018·Nature Medicine·Daniela S ThommenAlfred Zippelius
Citations
Sep 16, 2018·Nature Reviews. Clinical Oncology·Peter Sidaway
Jul 25, 2019·Cancers·Gabrielle Planes-LaineAnthony Gonçalves
Mar 30, 2019·Journal for Immunotherapy of Cancer·Gaia GriguoloAleix Prat
Sep 20, 2019·Journal for Immunotherapy of Cancer·Swati GuptaDavid L Rimm
Aug 25, 2019·The Oncologist·Federica MigliettaMaria Vittoria Dieci
Mar 30, 2020·The Journal of Pathology·Mei-Chun CaiGuanglei Zhuang
Jun 5, 2020·Cells·Federico PiñeroMário G Pessôa
Aug 17, 2019·Cancers·Leire PedrosaJoan Maurel
Aug 11, 2020·Experimental Hematology & Oncology·Yanhui ChenHenghui Zhang
May 28, 2019·Frontiers in Immunology·Kirill PeskovGabriel Helmlinger
Apr 3, 2020·Cancers·Anna DianaMichele Orditura
Nov 12, 2020·ESMO Open·Alexios MatikasTheodoros Foukakis
Dec 21, 2020·Molecular Oncology·Joan FrigolaRamon Amat
Aug 23, 2019·JAMA Oncology·Joo Sang Lee, Eytan Ruppin
Nov 23, 2019·Experimental Cell Research·Pei ChenJianFei Huang
Oct 27, 2020·Frontiers in Oncology·Evgeny N ImyanitovIlya V Tsimafeyeu
Apr 27, 2021·Expert Opinion on Emerging Drugs·Vineeth SukrithanBhavana Konda
May 1, 2021·Cancers·Natalia GeorgantzoglouStamatios Theocharis
May 12, 2021·Journal of Translational Medicine·Xintong LyuQiao Qiao
May 30, 2021·Molecular Oncology·Fara Brasó-MaristanyAleix Prat
Jul 27, 2021·Frontiers in Immunology·Xiaohan ZhouDehua Wu
Jul 22, 2021·International Journal of General Medicine·Quan MengXiaobin Lin
Jul 9, 2021·Cancer Treatment Reviews·Caroline BomanAlexios Matikas
Sep 1, 2021·Annals of Hematology·Ignacio IsolaCarlos Fernández de Larrea
Oct 5, 2021·Frontiers in Oncology·Zhenyu YangLunxu Liu
Dec 10, 2021·Frontiers in Medicine·Xiang-Bin RenYu-Zhu Xiang
Dec 14, 2021·Frontiers in Immunology·Jing SongLongke Ran